Literature DB >> 31435137

Hepatocellular Carcinoma: Combined Transarterial Chemoembolization and Ablation.

Josi L Herren1, Nerina Disomma1, Charles E Ray1.   

Abstract

Entities:  

Year:  2019        PMID： 31435137      PMCID： PMC6699963          DOI： 10.1055/s-0039-1694066

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN： 0739-9529            Impact factor:   1.513


× No keyword cloud information.
  35 in total

1.  Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply.

Authors:  S Rossi; F Garbagnati; R Lencioni; H P Allgaier; A Marchianò; F Fornari; P Quaretti; G D Tolla; C Ambrosi; V Mazzaferro; H E Blum; C Bartolozzi
Journal:  Radiology       Date:  2000-10       Impact factor: 11.105

Review 2.  Tolerance of normal tissue to therapeutic irradiation.

Authors:  B Emami; J Lyman; A Brown; L Coia; M Goitein; J E Munzenrider; B Shank; L J Solin; M Wesson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-05-15       Impact factor: 7.038

3.  Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy.

Authors:  Daniel B Brown; John F Cardella; David Sacks; S Nahum Goldberg; Debra A Gervais; Dheeraj Rajan; Suresh Vedantham; Donald L Miller; Elias N Brountzos; Clement J Grassi; Richard B Towbin
Journal:  J Vasc Interv Radiol       Date:  2006-02       Impact factor: 3.464

4.  Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma.

Authors:  Higinia R Cárdenes; Tracy R Price; Susan M Perkins; Mary Maluccio; P Kwo; T E Breen; Mark A Henderson; Tracey E Schefter; Kathy Tudor; Jill Deluca; Peter A S Johnstone
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

5.  Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients.

Authors:  H-X Xu; M-D Lu; X-Y Xie; X-Y Yin; M Kuang; J-W Chen; Z-F Xu; G-J Liu
Journal:  Clin Radiol       Date:  2005-09       Impact factor: 2.350

6.  Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.

Authors:  Xiang Da Dong; Brian I Carr
Journal:  Med Oncol       Date:  2010-11-24       Impact factor: 3.064

7.  Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors.

Authors:  Katsuhiro Kobayashi; Sanjay Gupta; Jonathan C Trent; Jean-Nicolas Vauthey; Savitri Krishnamurthy; Joe Ensor; Kamran Ahrar; Michael J Wallace; David C Madoff; Ravi Murthy; Stephen E McRae; Marshall E Hicks
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

8.  Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.

Authors:  Robert C G Martin; Jonathan Joshi; Ken Robbins; Dana Tomalty; Petar Bosnjakovik; Milous Derner; Radek Padr; Miloslav Rocek; Alexander Scupchenko; Cliff Tatum
Journal:  Ann Surg Oncol       Date:  2010-08-26       Impact factor: 5.344

9.  Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor.

Authors:  Takami Sato; David J Eschelman; Carin F Gonsalves; Mizue Terai; Inna Chervoneva; Peter A McCue; Jerry A Shields; Carol L Shields; Akira Yamamoto; David Berd; Michael J Mastrangelo; Kevin L Sullivan
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

Review 10.  Natural history of hepatocellular carcinoma and current treatment options.

Authors:  Jean-Luc Raoul
Journal:  Semin Nucl Med       Date:  2008-03       Impact factor: 4.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.